VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis

被引:135
作者
Ferrari, Giovanni
Pintucci, Giuseppe
Seghezzi, Graziano
Hyman, Kevin
Galloway, Aubrey C.
Mignatti, Paolo
机构
[1] NYU, Med Ctr, Seymour Cohn Cardiovasc Res Lab, Dept Cardiothorac Surg,Sch Med, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA
关键词
angiogenesis; MAPK kinase; p38; VEGF receptor; cancer;
D O I
10.1073/pnas.0605556103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
VEGF and TGF-beta 1 are potent angiogenesis inducers with opposing effects on endothelial cells. TGF-beta 1 induces apoptosis; VEGF protects endothelial cells from apoptosis. We found that TGF-beta 1 promotes endothelial cell expression of FGF-2, which up-regulates VEGF synthesis. Inhibition of VEGF signaling through VEGF receptor 2 (flk-1) abrogates TGF-beta 1-induced apoptosis and p38(MAPK) activation. Inhibition of p38(MAPK) blocks TGF-beta 1-induced apoptosis, showing that VEGF/flk-1-mediated activation of p38(MAPK) is required for TGF-beta 1 induction of apoptosis. In the absence of TGF-beta 1, VEGF activates p38MAPK and promotes endothelial cell survival. However, in context with TGF-beta 1, VEGF/flk-1-mediated activation of p38(MAPK) results in apoptosis. Thus, cross-talk between TGF-beta 1 and VEGF signaling converts VEGF/flk-1-activated p38(MAPK) into a proapoptotic signal. This finding illustrates an unexpected role of VEGF and indicates that VEGF can be pharmacologically converted into an apoptotic factor, a novel approach to antiangiogenesis therapy.
引用
收藏
页码:17260 / 17265
页数:6
相关论文
共 44 条
[1]   Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-β1 activity in endothelial cells [J].
Boström, K ;
Zebboudj, AF ;
Yao, YC ;
Lin, TS ;
Torres, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (51) :52904-52913
[2]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[3]   INHIBITION OF CAPILLARY MORPHOGENESIS AND ASSOCIATED APOPTOSIS BY DOMINANT-NEGATIVE MUTANT TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS [J].
CHOI, ME ;
BALLERMANN, BJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (36) :21144-21150
[4]   FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [J].
Cross, MJ ;
Claesson-Welsh, L .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) :201-207
[5]   Transforming growth factor-β1 potentiates renal tubular epithelial cell death by a mechanism independent of smad signaling [J].
Dai, CS ;
Yang, JW ;
Liu, YH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (14) :12537-12545
[6]  
DICKSON MC, 1995, DEVELOPMENT, V121, P1845
[7]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[8]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[9]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442
[10]   Angiogenesis as a therapeutic target [J].
Ferrara, N ;
Kerbel, RS .
NATURE, 2005, 438 (7070) :967-974